The Yale Cancer Center is committed to ensuring the safety of patients participating in clinical trials and requires all clinical trials conducted at the YCC adhere to the Yale Cancer Center (YCC) Data and Safety Monitoring Plan (DSMP). The original NCI approved./YCC DSMP was recently revised and approved by NCI in July of 2011. The plan outlines the scope of protocol oversight which is operationalized by the YCC Data and Safety Monitoring Committee (DSMC). While each investigator is responsible for the monitoring of a study, the initial scientific review conducted by the YCC Protocol Review Committee (PRC) includes the assignment of a more detailed protocol specific plan requiring additional oversight provided by the DSMC. For studies without external monitoring this includes a protocol specific schedule for safety review and internal auditing. The development of protocol specific monitoring plans and reporting requirements are dependent upon the overall risk to patients, the nature of the agent, the phase of the trial and prior safety data with the proposed treatment regimen, the role of the Yale principal investigator and the institution, and the study sponsor. The purpose of the DSMC is to provide ongoing data and safety monitoring for all interventional cancer clinical trials. The DSMC reviews all studies at least annually and has the authority to intervene in the conduct of these studies as necessary to ensure the safety of the participants and to maintain the highest quality in the clinical research performed at YCC. The Committee reviews safety data, audit findings, reports of unanticipated events, protocol deviations and requests for specific reviews from faculty, staff or study participants. The DSMC is chaired by Michal Rose, MD, Associate Professor of Medicine, and the Vice Chair is Ed Snyder, MD Professor of Laboratory Medicine each with over 13 years of clinical trials experience. The Office of Protocol Review and Monitoring (OPRM), headed by Susan Anderson, is the administrative arm of the DSMC which coordinates all DSMC activities, maintains records of all DSMC actions and provides staffing for internal audits and follow up on actions required as a resiJit of DSMC review or finding. OPRM also coordinates training programs for faculty and research staff, including. Good Clinical Practices (GCP), IRB Basics, Research Ethics and Misconduct, as well as specific topics key to the understanding of compliance and safety as they are identified and addressed as required.

Public Health Relevance

The DSMC is able to provide frequent checks on the activities of each therapeutic protocol in order to identify existing or potential problems that could affect patient safety and require corrective action plans to address such issues.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Wimberly, Hallie; Brown, Jason R; Schalper, Kurt et al. (2015) PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 3:326-32
Ma, Xiaomei; Wang, Rong; Long, Jessica B et al. (2014) The cost implications of prostate cancer screening in the Medicare population. Cancer 120:96-102
Herbst, Roy S; Soria, Jean-Charles; Kowanetz, Marcin et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7
Durazzo, Tyler S; Tigelaar, Robert E; Filler, Renata et al. (2014) Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus Apher Sci 50:370-8
Black, Jonathan D; English, Diana P; Roque, Dana M et al. (2014) Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) 10:45-57
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Cao, Jian; Liu, Zongzhi; Cheung, William K C et al. (2014) Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep 6:868-77
Gonzalez, A L; Berger, C L; Remington, J et al. (2014) Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clin Exp Immunol 175:449-57
O'Malley, Stephanie S; Wu, Ran; Mayne, Susan T et al. (2014) Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 16:1145-9
Chen, Lieping (2014) From the guest editor: Tumor site immune modulation therapy. Cancer J 20:254-5

Showing the most recent 10 out of 72 publications